Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218129

SCHEMBL23218129

SCHEMBL23218129

CCOC(=O)C(C(C)=O)c1cc(Cl)cc(Br)c1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 2/20 0.36
▸ HPGD P15428 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ NPSR1 Q6W5P4 3/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ TP53 P04637 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ APAF1 O14727 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592028 0.89 MAOB (0.35) MAOBHPGDKMT2ANPSR1KDM4E
SCHEMBL23218699 0.89 MAOB (0.35) MAOBHPGDKMT2ANPSR1KDM4E
SCHEMBL23218269 0.78 MAOB (0.39) MAOBHPGDKMT2ANPSR1KDM4E
SCHEMBL23218551 0.75 DRD2 (0.43) MAOBKDM4ESMN1; SMN2L3MBTL1THRB
SCHEMBL23218478 0.66 MAOB (0.38) MAOBHPGDKMT2ANPSR1KDM4E
SCHEMBL8027004 0.66 CYP3A4 (0.47) HPGDKMT2AKDM4EMEN1LMNA
SCHEMBL29337434 0.65 MAOA (0.31) MAOBMAOA
SCHEMBL16068909 0.64 CYP3A4 (0.43) HPGDKMT2AMEN1LMNATP53
SCHEMBL7477920 0.64 MMP8 (0.42) MAPTMAPK1ALDH1A1L3MBTL1DRD2
SCHEMBL16344468 0.63 S1PR3 (0.40) KMT2ANPSR1KDM4EMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAOB 1035/4885HPGD 695/4885KMT2A 4445/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAOB 453/4885HPGD 323/4885KMT2A 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.